Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trxade Group (MEDS) has issued an announcement.
On July 25, 2024, TRxADE HEALTH, INC. finalized a merger with Scienture, Inc., wherein Scienture became a wholly owned subsidiary and subsequently merged with the Company’s subsidiaries, leading to a rebranding as Scienture Holdings, Inc. This strategic move aims to leverage Scienture’s expertise in pharmaceutical research and its portfolio of innovative products targeting unmet medical needs. Shareholders of Scienture received a mix of common and preferred shares in the newly formed entity, with the preferred shares set to convert under certain conditions, enhancing value and potential growth for investors.
For a thorough assessment of MEDS stock, go to TipRanks’ Stock Analysis page.